Russian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

ototoxicity/диарея

Ссылка сохраняется в буфер обмена
Страница 1 от 33 полученные результаты

Sudden hearing loss subsequent to diarrhea: what is the missing link?

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Sudden sensorineural hearing loss (SSNHL) is a debilitating condition with an incidence of nearly 20 per 100,000 in populations. Metronidazole-induced ototoxicity is an extremely rare etiology of SSNHL. In this report, we describe a young female with bilateral SSNHL due to oral use of metronidazole.

An Unusual Case of Ototoxicity with Use of Oral Vancomycin.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
UNASSIGNED Systemic absorption of oral vancomycin is poor due to the size of the molecule and its pharmacokinetics. It has an elimination half life of 5-11 hours in patients with normal renal function. We present a rare case of ototoxicity after oral vancomycin administration and detectable serum

[Vancomycin intoxication in a patient with inappropriate antidiuretic hormone syndrome and diarrhea].

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Vancomycin is an antibiotic used for infections by gram-positive bacteria with a two-compartment pharmacokinetic model. Its monitoring has an established therapeutic range (10-20 mg/L) to prevent nephrotoxicity and ototoxicity due to supratherapeutic levels, and inefficiency and development of

API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
BACKGROUND The World Health Organization (WHO) has declared Tuberculosis (TB) a global emergency in 1993. Prevalence of TB and Human Immunodeficiency Virus (HIV) co-infection worldwide is 0.18% and about 8% TB cases have HIV infection. Effective chemotherapy has been available for treatment of TB

[Bilateral vestibular loss as a post-infection complication of yersiniosis?].

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
BACKGROUND Yersinia infections other than plaque are caused by Yersinia pseudotuberculosis and Yersinia enterocolitica. Food and water contamination as well as animal-to-person and person-to-person contact are common pathways of transmission. Clinical manifestations include enteritis, enterocolitis,

Phase I study of difluoromethylornithine in combination with recombinant alpha 2a-interferon.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
24 patients with advanced, histologically proven cancer were treated with difluoromethylornithine 2.25 g/m2 orally every 6 h for the first 7 days of each 4-week treatment cycle. These patients also received daily i.m. doses of recombinant human alpha 2a-interferon (IFN) on Days 3 through 7 of each

High-dose carboplatin in the treatment of hematologic malignancies.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Carboplatin is a second-generation platinum complex developed to be less ototoxic and nephrotoxic than cisplatin. The major toxicity was found to be myelosuppression; thus, it was tried in acute leukemia. When given by daily bolus injection for 5 days, carboplatin exhibited some activity but was

Intra-arterial cisplatin for bladder cancer.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Cisplatin (25 to 120 mg. per m.2) was injected into the internal iliac arteries of 33 patients with locally advanced bladder cancer. Of the patients 9 were inevaluable for response to the cisplatin, since they began radiotherapy to the bladder before course 2 of cisplatin as part of a preplanned

Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
BACKGROUND Poor treatment results obtained with palliative chemotherapy for advanced gastric cancer indicate the need for new effective and well-tolerated regimens. METHODS Forty-three patients with locally advanced or metastatic gastric cancer were enrolled in a phase II study to evaluate the

Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
BACKGROUND This Phase I trial aimed to determine the maximum-tolerated-dose of erlotinib administered with two standard chemoradiotherapy regimens for non-small cell lung cancer. METHODS Unresectable stage III non-small cell lung cancer patients were enrolled in this 2-arm dose-escalation study.

Safety and toxicity profile of aztreonam.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Aztreonam is the first monocyclic beta-lactam antibiotic released for clinical use. Extensive toxicity and safety data for aztreonam in animals, healthy volunteers and adult patients have been accumulated previously; recently these studies have been extended to children. Overall the incidence of

Invasive bladder carcinoma: a pilot study of conservative treatment with accelerated radiotherapy and concomitant cisplatin.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
From November 1992 to December 1997, 25 patients (inoperable or refusing cystectomy) were included in a prospective study to assess the feasibility, tolerance, and curative potential of accelerated radiotherapy (RT) and concomitant cisplatin. Median age was 74 years (range 49-86). Stage distribution

Phase I trial of i.v. administered tirapazamine plus cyclophosphamide.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Our objective was to determine the maximum tolerated doses of tirapazamine and cyclophosphamide given i.v. in combination. Eligible patients had advanced solid tumors refractory to conventional treatment. Tirapazamine (escalated from 80 to 390 mg/m(2)) was given i.v. over 2 h and followed by

Considerations regarding clinical safety and tolerability of antibiotics in serious and nosocomial infections.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Patients with severe gram-negative infections are often treated with aminoglycosides, cephalosporins, or a combination of these. Aminoglycosides cause nephrotoxicity and ototoxicity. Duration of treatment and dose are directly related to the incidence of toxicity. Nephrotoxicity occurs in 10% to 20%

Cisplatin, vinblastine, and mitoguazone chemotherapy for epidermoid and adenocarcinoma of the esophagus.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Thirty-six patients with adenocarcinoma or epidermoid carcinoma of the esophagus were entered into a phase II trial evaluating the combination of cisplatin 100 mg/m2 intravenously (IV) day 2, vinblastine 1.6 mg/m2 IV days 1 to 4, and mitoguazone (MGBG) 500 mg/m2 IV days 1 and 8. Twenty-nine patients
Присоединяйтесь к нашей
странице facebook

Самая полная база данных о лекарственных травах, подтвержденная наукой

  • Работает на 55 языках
  • Травяные лекарства, подтвержденные наукой
  • Распознавание трав по изображению
  • Интерактивная карта GPS - отметьте травы на месте (скоро)
  • Прочтите научные публикации, связанные с вашим поиском
  • Ищите лекарственные травы по их действию
  • Организуйте свои интересы и будьте в курсе новостей исследований, клинических испытаний и патентов

Введите симптом или заболевание и прочтите о травах, которые могут помочь, введите лекарство и узнайте о болезнях и симптомах, против которых оно применяется.
* Вся информация основана на опубликованных научных исследованиях.

Google Play badgeApp Store badge